ArticleFrontiers in behavioral neuroscience2026
Examining aggressive behavior in patients with epilepsy under treatment with Levetiracetam, Brivaracetam and Perampanel: a comparison to healthy controls.
Article in Frontiers in behavioral neuroscience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Epilepsy is frequently associated with behavioral and emotional difficulties. Among antiseizure medications, Levetiracetam, Perampanel, and Brivaracetam are notorious to cause behavioral adverse drug reactions, including increased anger, irritability, and aggression. While these effects are often described in self-report data, experimental studies examining aggressive behavior in patients with epilepsy are scarce. This study aims to assess aggression in patients with epilepsy and compare it to healthy controls, using self-report measures and two experimental provocation paradigms. Methods: Thirty seven patients with epilepsy treated with Levetiracetam, Perampanel, or Brivaracetam (with an overrepresentation of patients treated with Levetiracetam) and 38 healthy controls completed the Buss and Perry Aggression Questionnaire, Barratt Impulsiveness Scale, Beck's Depression Inventory, and Affective Style Questionnaire. Aggressive behavior and reaction were investigated using a modified version of the Taylor Aggression Paradigm and the Technical Provocation Paradigm, alongside with emotional state ratings during the paradigms. Results: Patients with epilepsy reported higher aggression, impulsivity, and depression in the self-report questionnaires compared to healthy controls. However, behaviorally, patients did not show increased aggression. Instead, they showed reduced emotional reactivity to provocation, with lower changes in the emotional state ratings. Higher desire for revenge and higher frustration during the task predicted stronger aggressive responses in the patient group, but not in the control group. Discussion: Our findings suggest reduced emotional responsiveness to provocation, and a discrepancy between self-perceived and observed aggression in patients with epilepsy. Aggressive responses in this group appeared to be influenced by situational emotions such as revengefulness and frustration. These results underline the need to differentiate between subjective and observable behavioral changes in patients with epilepsy, and of considering the impact of psychiatric comorbidities and emotion regulation difficulties.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.